These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7090422)

  • 21. Disposition and metabolism of adriamycin in the rat.
    Tavoloni N; Guarino AM
    Pharmacology; 1980; 21(4):244-55. PubMed ID: 7422708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
    Cusack BJ; Young SP; Olson RD
    Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced antitumor activity of adriamycin in combination with allopurinol.
    Schwartz HS
    Cancer Lett; 1983 Aug; 20(1):69-74. PubMed ID: 6689280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1977 Feb; 26(3):215-22. PubMed ID: 14644
    [No Abstract]   [Full Text] [Related]  

  • 25. Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells.
    Le Bot MA; Glaise D; Kernaleguen D; Ratanasavanh D; Carlhant D; Riche C; Guillouzo A
    Pharmacol Res; 1991 Oct; 24(3):243-52. PubMed ID: 1659695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytofluorescence localization of adriamycin and daunorubicin.
    Egorin MJ; Hildebrand RC; Cimino EF; Bachur NR
    Cancer Res; 1974 Sep; 34(9):2243-5. PubMed ID: 4843531
    [No Abstract]   [Full Text] [Related]  

  • 27. Initial biotransformations of daunorubicin to aglycones by rat liver microsomes.
    Schwartz HS; Parker NB
    Cancer Res; 1981 Jun; 41(6):2343-8. PubMed ID: 7237433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodistribution of intravenously injected [14C] doxorubicin and [14C] daunorubicin in mice: concise communication.
    Harrison K; Wagner NH
    J Nucl Med; 1978 Jan; 19(1):84-6. PubMed ID: 621570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.
    Behnia K; Boroujerdi M
    J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart.
    Platel D; Bonoron-Adèle S; Robert J
    Pharmacol Toxicol; 2001 May; 88(5):250-4. PubMed ID: 11393585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D.
    Terasaki T; Iga T; Sugiyama Y; Sawada Y; Hanano M
    J Pharmacobiodyn; 1984 May; 7(5):269-77. PubMed ID: 6470925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PB-PK derived metabolic constants, hepatotoxicity, and lethality of BrCCl3 in rats pretreated with chlordecone, phenobarbital, or mirex.
    Thakore KN; Gargas ML; Andersen ME; Mehendale HM
    Toxicol Appl Pharmacol; 1991 Jul; 109(3):514-28. PubMed ID: 1712992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic activation of adriamycin by NADPH-cytochrome P-450 reductase, rat liver and heart microsomes and covalent protein binding of metabolites.
    Scheulen ME; Kappus H
    Adv Exp Med Biol; 1981; 136 Pt A():471-85. PubMed ID: 6807062
    [No Abstract]   [Full Text] [Related]  

  • 35. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.
    Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T
    Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration of chromatin structure induced by the binding of adriamycin, daunorubicin and ethidium bromide.
    Grimmond HE; Beerman T
    Biochem Pharmacol; 1982 Nov; 31(21):3379-86. PubMed ID: 7150361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei.
    Frezard F; Garnier-Suillerot A
    Biochim Biophys Acta; 1990 Nov; 1036(2):121-7. PubMed ID: 2223830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits.
    Hulhoven R; Harvengt C
    Pharmacology; 1982; 24(4):253-60. PubMed ID: 7089047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species.
    Yesair DW; Schwartzbach E; Shuck D; Denine EP; Asbell MA
    Cancer Res; 1972 Jun; 32(6):1177-83. PubMed ID: 5030818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.